High level of pre-treatment C-reactive protein to albumin ratio predicts inferior prognosis in diffuse large B-cell lymphoma.

ABSTRACT: The C-reactive protein-to-albumin ratio (CAR) has not been assessed in diffuse large B cell lymphoma (DLBCL, the most common non-Hodgkin lymphoma). This retrospective study evaluated the prognostic value of CAR in 186 DLBCL patients. A CAR value of 0.158 was selected as the most discriminative cut-off for identifying patients with high CAR values (73/141 patients, 51.8%). During a median follow-up of 32.5 months, the high CAR group had significantly poorer complete response to induction therapy (64.4% vs. 92.6%; p??0.158 also showed worse 3-year OS (47.9% vs. 87.2%, p?=?0.0035) and 3-year PFS (36.1% vs. 82.1%, p?=?0.0011). A high CAR remained significantly associated with poor outcomes for?>?60-year-old patients (OS: p?=?0.0038, PFS: p?=?0.0015) and younger patients (OS: p?=?0.0041, PFS: p?=?0.0044). Among older patients, a high CAR value also predicted non-relapse mortality (p?=?0.035). Therefore, the CAR might complement the International Prognostic Index in DLBCL cases.

SUBMITTER: Jung J 

PROVIDER: S-EPMC7846592 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature